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Allogeneic hematopoietic stem cell transplantation (HSCT) has become an established treatment modality for
various hematological diseases. However, in allogeneic HSCT, patients often suffer from severe gastrointes-
tinal complications caused by the conditioning regimen and acute/chronic graft-versus-host disease, which
requires support by multidisciplinary nutritional support teams (NST). In addition, pretransplantation
nutritional status can affect the clinical outcome after allogeneic HSCT. Therefore, it is important to refer the
patient to a NST when becoming aware of nutritional problems before allogeneic HSCT. It is also important to
follow nutritional status over the long term, as patients often suffer from various nutritional problems, such
as malnutrition and metabolic syndrome, even late after allogeneic HSCT. In summary, NST can contribute to
the improvement of nutritional status and possibly prognosis at every stage before and after allogeneic HSCT.
Here, we aim to give a comprehensive overview of current understanding about nutritional support in
allogeneic HSCT and try to provoke a constructive discussion to stimulate further investigation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION support teams (NST) is indispensable in all processes of
Allogeneic hematopoietic stem cell transplantation
(HSCT) has become an integral part in the treatment of he-
matological malignancies. As pretransplantation nutritional
status affects post-transplantation complications and out-
comes, nutritional intervention is highly important before
allogeneic HSCT. Additionally, the conditioning regimen,
including intensive chemotherapy and total body irradiation,
may cause severe side effects, such as mucositis, nausea,
vomiting, and diarrhea, resulting in insufﬁcient oral intake
and extensive malabsorption and malnutrition via the
gastrointestinal tract. During regimen-related toxicity, there
is no doubt that nutritional support plays an important role
in addressing these acute and clearly therapy-related prob-
lems. In addition, more attention has recently been paid to
the long-term management of HSCT recipients, as malnu-
trition may signiﬁcantly affect the clinical course and the
patients’ quality of life, even late after allogeneic HSCT. Thus,
professional intervention by multidisciplinary nutritionaldgments on page 1711.
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ty for Blood and Marrow Transplantation.allogeneic HSCT (Figure 1).
We believe that there is still room for improvement in the
management strategy of nutritional support in the ﬁeld of
HSCT. It seems that clinical daily practice varies among
different countries [1,2]. It is important to share the knowl-
edge and experience of experts in this ﬁeld. In this article, we
aim to provide a comprehensive overview of the current
understanding about nutritional support in HSCT, to give the
clinician treating allogeneic HSCT patients ideas for daily
practice, and to provoke a meaningful discussion about
this important topic of supportive care in allogeneic HSCT
recipients.PRETRANSPLANTATION ASSESSMENT AND
INTERVENTION
Three prognostic factors relating to nutritional status are
included in hematopoietic cell transplantation-comorbidity
index: obesity, diabetes mellitus (DM), and liver dysfunc-
tion [3]. Globally, the prevalence of obesity and DM is
rapidly increasing [4-6]. Although liver dysfunction may
appear unrelated to nutritional status, the most common
cause of liver dysfunction currently is nonalcoholic fatty
liver disease (NAFLD) [7]. Therefore, we expect that more
Figure 1. Role of nutritional support teams in the course of allogeneic HSCT.
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which may increase the risk of morbidity and mortality
after HSCT.
In terms of body weight, several retrospective studies
have shown the impact of pretransplantation body mass
index (BMI) on the clinical outcome after allogeneic HSCT
[8-16]. The results varied, but there is a clear trend of high
BMI being associated with an increased risk of graft-versus-
host disease (GVHD) and nonrelapse mortality (NRM) and
low BMI being associated with inferior overall survival
because of an increased risk of relapse and NRM. Even
though the mechanism of how BMI affects the clinical
outcome is unclear [17], it is reasonable to attempt to opti-
mize pretransplantation BMI by intervening during chemo-
therapy before allogeneic HSCT. For example, obese patients
can lose body weight through nutritional intervention and
exercise [18]. In contrast, patients with malnutrition can
improve their nutritional status with nutritional support. In
general, consulting with specialized NST to optimize the
nutritional status of candidates for HSCT during chemo-
therapy [19] is of great importance.
Regarding DM, pretransplantation DMwas reported to be
associated with increased risk of NRM [3,20,21]. In particular,
pretransplantation DM signiﬁcantly increased the risk of
invasive fungal diseases [20-22]. The mechanism is unclear,
but increased risk may be due to impaired neutrophil func-
tion in patients with DM [23,24]. Consulting with an endo-
crinologist and dietitian to control DM in patients with DM is
recommended, although it is unclear whether better control
of DM can mitigate the adverse impact of DM [25]. A study
that assessed the effect of pretransplantation glucose control
on the clinical outcome after HSCT is warranted. In addition,
elevated c-peptide was reported to be a risk factor for post-
transplantation DM [26]. Therefore, patients with poor
pretransplantation glucose control should be treated inconsultation with an endocrinologists to reduce the risk of
post-transplantation DM [25].
Regarding NAFLD, there is no clear evidence that NAFLD
itself has an adverse impact on the clinical outcome after
HSCT. However, it is well known that patients with pre-
transplantation liver dysfunction have increased risk of
sinusoidal obstructive syndrome and NRM [3,27-30]. In pa-
tients with NAFLD, weight loss and lifestyle modiﬁcation are
recommended [7].
NUTRITIONAL MANAGEMENT DURING THE EARLY
PERIOD AFTER HSCT
A conditioning regimen including intensive chemo-
therapy and total body irradiation may cause severe side
effects, such as mucositis, nausea, vomiting, and diarrhea,
resulting in insufﬁcient oral intake and gastrointestinal
absorption. Although a large proportion of patients currently
receives a reduced-intensity conditioning regimen, which
causes much less gastrointestinal toxicity, it is still common
for patients to be unable to maintain adequate oral intake
[31].
Regarding the target caloric intake after HSCT, 25 to
30 kcal/kg/day is usually recommended for patients without
severemalnutrition [32,33]. In patients withmalnutrition, an
increased target caloric intake, such as 35 to 45 kcal/kg/day,
is recommended. However, we have to keep in mind that
such a high calorie intake is inevitably associated with hy-
perglycemia after HSCT and is not used in recent trials, even
in the intensive care unit (ICU) [34].
In patients with insufﬁcient caloric intake, parenteral
nutrition (PN) is still the most commonly used source of
nutrition after HSCT to maintain the minimum requirement
of caloric intake. Use of PN only when necessary is important
to reduce the risk of complications associated with PN
[35,36], as excessive PN may lead to various complications,
Figure 3. Theoretical relationship between hyperglycemia and post-
transplantation complications.
S. Fuji et al. / Biol Blood Marrow Transplant 21 (2015) 1707e1713 1709such as hyperglycemia, fatty liver, and ﬂuid overload
(Figure 2). Patients may lose weight if minimum calorie
intake is not met [37], which appears to be associated with a
subsequent risk of comorbidities [38]. Glucose intake should
remain lower than 5 g/kg/day [32,33] and lipids should be
used to cover the caloric intake. The proportion of lipid in PN
is usually 20% to 30% of total calories. As higher doses of
glucose by PN is associated with increased risk of hypergly-
cemia [39], it is important to increase fat content to reduce
the proportion of glucose in patients with uncontrolled
hyperglycemia [40].
Use of enteral nutrition (EN) can be an important alter-
native, as Seguy et al. reported the possible beneﬁt using EN
after HSCT [41-43]. Using the gut might be beneﬁcial to
maintain its integrity or improve glucose control, which may
reduce the risk of GVHD [41,42,44]. Other groups also re-
ported feasibility and promising results of using EN after
HSCT [45-47]. The major limitation of EN in HSCT is the dif-
ﬁculty of inserting EN tubes in patients with severemucositis
or gastrointestinal tract damage. A prospective randomized
controlled trial is ongoing in France, comparing PN and EN
after myeloablative HSCT (NEPHA study, Clinical trials gov
number: NCT01955772) [48].
Further, glucose control is important during the early
period after HSCT. DM is well known to increase the risk of
infectious diseases, which are caused by impaired neutrophil
and other immune cells’ dysfunction [23,24]. Hyperglycemia
causes not only impaired immune function but also causes
problems with other tissues, such as endothelial dysfunction,
elevation of proinﬂammatory cytokines, catabolism of mus-
cle and fat, and procoagulation, all of which may be relevant
in patients after allogeneic HSCT (Figure 3) [23,24]. Theo-
retically, hyperglycemia itself can increase the level of cyto-
kines and hyperglycemia can increase the risk of infectious
diseases as described above, which might lead to a subse-
quent increased risk of GVHD that further exaggerates hy-
perglycemia, creating a vicious cycle. As mentioned earlier,
pretransplantation DM is shown to be a risk factor for NRM,
which suggests the importance of glucose control in HSCT
[3,20,21]. Several retrospective studies have shown that
post-transplantation hyperglycemia was associated with an
increased risk of morbidity and mortality after HSCT [49-53].
Patients who receive glucocorticosteroids as GVHD treat-
ment are at high risk of suffering from dysglycemia, which is
associated with inferior clinical outcomes. Hyperglycemia
associated with systemic glucocorticoid for GVHD is oftenFigure 2. Possible correlation between nutritional intake and clinical beneﬁt.difﬁcult to control and frequently requires the consultation
with endocrinologist [54]. Improving glucose control may
lead to a reduced risk of such post-transplantation compli-
cations. Although several studies conducted in the ICU casted
doubt on the beneﬁt of intensive glucose control (IGC) [55],
studies that failed to show the beneﬁt of IGC and were not
able to achieve sufﬁcient glucose control were criticized [56].
We assume that glucose control is feasible in patients after
HSCT because patients usually receive PN, as Leuven studies
[55,57,58]. Therefore, our group conducted a small prospec-
tive study to assess the feasibility and effectiveness of IGC
after allogeneic HSCT [11]. Even though this study was small,
there were no serious complications relating to hypoglyce-
mia and there was signiﬁcantly less documented infection in
patients undergoing IGC compared with the matched-
control group. To further test the efﬁcacy and safety of IGC,
a multicenter clinical trial incorporating IGC in patients who
received allogeneic HSCT using a myeloablative conditioning
regimen was conducted in Japan; we are now collecting data
(UMIN000001189). Without established evidence in patients
who undergo allogeneic HSCT, it may be reasonable to target
blood glucose level as recommended for noncritically ill
patients by the American Diabetes Association (ADA)/
American Association of Clinical Endocrinologists (fasting
glucose <140 mg/dL [7.8 mmol/L] and random glucose
<180 mg/dL [10.0 mmol/L]) [59,60]. Adding insulin in the PN
bag is practical and safe to control glucose level as recom-
mended [61-63]. In general, 1 unit of regular insulin per 10 g
of glucose in the PN bag is a starting dose for patients who do
not have hyperglycemia [61-63]. Patients using glucocorti-
costeroids usually need a higher dose of insulin because of
the increased insulin resistance associated with glucocorti-
costeroids. Although sliding-scale insulin is commonly used
in the hematology unit, sliding-scale insulin alone is not
recommended because it does not contribute to the better
control of glucose level, as reported previously [64,65]. In-
sulin administration in hospitalized patients should include
3 components to be effective: basal insulin, nutritional in-
sulin, and correctional insulin [24,65]. The protocol has to be
adjusted in each patient by experienced endocrinologists. In
practice, basal insulin is covered by the addition of regular
insulin in the PN bag. In patients without PN but with an
elevated fasting glucose level, long-acting insulin, such as
insulin degludec and insulin glargine, is used as basal insulin.
Although the starting dose can vary depending on the level
of glucose and insulin resistance, .3 unit/kg/day is a reason-
able starting dose, which may be adjusted by an endocri-
nologist. Nutritional insulin is important in patients with
hyperglycemia who can take food orally. In particular,
Figure 4. Association between chronic GVHD and malnutrition.
S. Fuji et al. / Biol Blood Marrow Transplant 21 (2015) 1707e17131710patients who receive systemic steroids often experience
postprandial hyperglycemia. Such patients need ultra-fast
acting insulin, such as Insulin Glulisin. Correctional insulin
is used to adjust the dose of insulin after determining the
actual glucose level. The dose of correctional insulin should
be used to adjust the dose of basal insulin and nutritional
insulin.
Glutamine
Glutamine, a conditionally essential amino acid that is
also an essential nutrient for some cells, such as enterocytes
and lymphocytes, is attractive nutrient [66]. After HSCT,
glutamine may minimize damage of the intestine associ-
ated with conditioning regimen. The effect of glutamine on
glucose homeostasis might be beneﬁcial for patients after
allogeneic HSCT [67,68]. Several small prospective studies
have assessed the impact of glutamine on the outcome in
HSCT [69-74], and in meta-analyses, the use of glutamine
was associated with beneﬁcial effects [75,76]. There appear
to be some beneﬁts from oral glutamine in reducing
mucositis and GVHD, whereas intravenous glutamine may
reduce infections. However, each trial was rather small and
the dose/underlying disease was heterogeneous. Recent
large randomized controlled trials in ICU settings showed
detrimental effects of supplemental glutamine in critically
ill patients, in particular in patients with renal dysfunction
[77-79]. Although the mechanism of glutamine’s detri-
mental effects in critically ill patients is unclear, nutritional
support including high-dose glutamine may lead to an
overload of amino acid in patients with renal dysfunction.
In fact, the proportion of patients with high urea was
signiﬁcantly higher in patients who received supplemental
glutamine [77]. Thus, one has to be careful when using
glutamine in patients with renal dysfunction after alloge-
neic HSCT. Larger, well-designed studies in patients after
allogeneic HSCT are required to conﬁrm possible beneﬁcial
effects.
Omega Three Fatty Acid
Omega 3 fatty acid is also an attractive nutritional
component. Omega 3 fatty acid plays a role as an immuno-
modulatory factor [80]. Theoretically, omega 3 fatty acid
might mitigate the cytokine storm and contribute to a
reduced incidence of complications after HSCT. A small study
showed a possible beneﬁt with omega 3 fatty acid, such as
less severe GVHD, in allogeneic HSCT, but larger studies are
necessary to conﬁrm this ﬁnding [81]. Regarding intravenous
omega 3 fat emulsion, some reports showed the feasibility
and effectiveness in reversing PN-associated liver disease in
patients with short bowel syndrome [82]. Therefore, intra-
venous omega 3 fatty acid might be beneﬁcial in patients
who require long-term PN with both gut GVHD and liver
dysfunction after allogeneic HSCT. In addition, when we
encounter patients with hypertriglycemia after HSCT, we
usually reduce the dose of lipid [33]. However, adding omega
3 fatty acid might be useful in maintaining the proportion
of caloric intake from lipids and the optimal level of tri-
glycerides [83].
The optimal doses of other micronutrients are not well
established in HSCT. For instance, a recent study showed that
vitamin C deﬁciency was prominent throughout the acute
phase of HSCT and this was signiﬁcantly associated with high
inﬂammatory markers [84]. Considering vitamin C’s role as
an antioxidant, an increased dose of vitamin C might be
beneﬁcial after HSCT.The subject of nutritional support in patients with GVHD
was nicely reviewed recently [85]. Further, manipulating
intestinal microbiota by prebiotics/probiotics may also be an
important, which was also reviewed recently [86].
NUTRITIONAL MANAGEMENT IN LONG-TERM FOLLOW-
UP UNIT
After discharge, patients can experience various problems
relating to nutrition, such as undernutrition due to insufﬁ-
cient oral intake or metabolic disorders, such as DM, obesity,
dyslipidemia, and hypertension.
Regarding undernutrition, weight loss is rather common
after allogeneic HSCT [38,87-93]. Our group reported that
severe weight loss ( 10% weight loss in 3 months) after
allogeneic HSCT was associated with an increased risk of
subsequent NRM, which led to a poor overall survival [38].
Bassim et al. also reported that patients with malnutrition
had inferior outcomes compared with those without
malnutrition. In particular, patients with chronic GVHD of
the mouth, gastrointestinal tract, and lung tend to lose sub-
stantial body weight (Figure 4) [91]. Although malnutrition
can reﬂect the severity of chronic GVHD in most patients, we
also encounter patients who do not have a typical manifes-
tation of chronic GVHD but lose body weight as in wasting
syndrome. It is possible that subclinical inﬂammations after
allogeneic HSCT lead to such a condition [94,95]. Although
the most important intervention is the correct treatment of
chronic GVHD itself, consulting NST is recommended when
patients lose weight [96].
On the other hand, metabolic syndrome is also common
in survivors after allogeneic HSCT [97-99]. Considering the
high prevalence of cardiovascular disease after allogeneic
HSCT [100-102], regular screening after allogeneic HSCT is
recommended for individual components of metabolic syn-
drome: blood pressure (hypertension), fasting lipid (dysli-
pidemia), fasting glucose, and HbA1c/glycated albumin
(diabetes). Routine screeningwill help in initiating treatment
of each risk factor, whichmay subsequently reduce the risk of
cardiovascular disease in long-term survivors after alloge-
neic HSCT. A signiﬁcant proportion of patients after alloge-
neic HSCT develop DM, a component of metabolic syndrome
[103]. Patients treated with glucocorticoid, in particular, have
high risk of developing DM. Although there is no speciﬁc
guideline indicating how to treat patients with DM after
HSCT, it is reasonable to treat them as one would treat a
nontransplantation patients with DM [59]. Following the
Standards of Medical Care in Diabetes by the ADA, the target
of each parameter can be summarized as follows: prepran-
dial capillary plasma glucose, 70 to 130 mg/dL (3.9 to
7.2 mmol/L); peak postprandial capillary plasma glucose,
<180 mg/dL (<10.0 mmol/L); and HbA1c, <7.0% [59,60]. If
S. Fuji et al. / Biol Blood Marrow Transplant 21 (2015) 1707e1713 1711the lower targets can be achieved without signiﬁcant hypo-
glycemia or other adverse effects of treatment, HbA1c< 6.5%
is an appropriate target, as supported by the ADA/American
Association of Clinical Endocrinologists [59,60]. To achieve
this target HbA1c level, fasting blood glucose may need to
be < 110 mg/dL and the 2-hour postprandial glucose may
need to be < 140 mg/dL. In patients with unreliable HbA1c
level, fructosamine or glycated albumin, which are not
affected by the stability of red blood cells, can be an alter-
native marker to assess control of glucose level [104]. It is
important to pay much attention to other risk factors for
cardiovascular disease in patients with DM [59].
CONCLUSION
As described above, nutritional support plays an impor-
tant role in allogeneic HSCT, although optimal management
has not yet beenwell established. We should conduct clinical
studies including both retrospective and prospective studies
to optimize nutritional support in this ﬁeld, which is believed
to improve the clinical outcome after HSCT.
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